



EUROPEAN COMMISSION  
DIRECTORATE GENERAL  
JOINT RESEARCH CENTRE  
Directorate F – Health, Consumers and Reference Materials  
Unit F1 Health in Society

## European Commission Initiative on Breast Cancer (ECIBC) Annual Declaration of Interests<sup>1</sup> (DoI) form (version n°2)

**Please answer each of the questions below.**

*(Please insert rows as needed for subsequent or parallel activities of the same nature)*

The questions refer to the last five years of activity (January 2017- December 2021).

If the answer to any of the questions is "Yes", please complete the corresponding fields, describing relevant interests and circumstances, as appropriate.

If it is not clear under which category of the form to declare an interest, you can declare it under "Other activities".

If you do not disclose relevant activities of interest for the ECIBC, your role as a working group member may be revised.

If you do not submit a filled-in and signed DoI form, you cannot be involved in the ECIBC activities.

---

<sup>1</sup>According to European Commission's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 11 each member of an expert group has to complete a DoI form  
[https://ec.europa.eu/transparency/documents-register/detail?ref=C\(2016\)3301&lang=en](https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en)

**Definitions and/or explanations:**

**"Conflict of interest"** represents a set of conditions in which professional judgment concerning a primary interest such as the health and well-being of a patient or the validity of research is improperly influenced by a secondary interest.

**"Immediate family member"** includes the individual's spouse, children and parents, irrespective whether they live at the same address or not.

**"Spouse"** includes a partner with whom the individual has a registered marital or non-marital regime.

**"Children"** refers to the child(ren) the individual and the spouse have in common, the own child(ren) of the individual and the own child(ren) of the spouse.

In the corresponding section of the DoI form, please declare (if any) current direct interests related to the topic of breast cancer, i.e. employment, consultancy, strategic advisory role, financial interests, of your immediate family members.

**"Legal entity"** is any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

**"Body"** implies a governmental, international or non-profit organisation.

**"Meeting"** includes a series or cycle of meetings.

**"BC"** refers to breast cancer.

**Name and Surname:**

Activities in the last five years (January 2017- December 2021)	Yes/No	Period (From – To)	Information	Details
<p>1. Did you have ownership or financial investments, including stocks or shares in a legal entity with relevance to the topics of the ECIBC which either:</p> <ul style="list-style-type: none"> <li>• have a value of more than 10.000 EUR,</li> </ul> <p>or</p> <ul style="list-style-type: none"> <li>• entitle you to a voting right of 5% or more?</li> </ul>	<p>Yes <input type="checkbox"/></p> <p>No <input checked="" type="checkbox"/></p>	<p>01/2017 – 12/2021</p>	<p>Please provide information about the entities in which the financial interest is placed (Name, Country, Public/Private).</p>	<p>[Please describe the entity and your role.]</p>
<p>2. Did you have a remunerated or non-remunerated position (including consultancy) in a legal entity with relevance to the topics of the ECIBC?</p>	<p>Yes <input type="checkbox"/></p> <p>No <input checked="" type="checkbox"/></p>	<p>01/2017 – 12/2021</p>	<p>Please specify:</p> <ul style="list-style-type: none"> <li>• Name, Place of the entity;</li> <li>• Type of the entity: public, private, etc.;</li> <li>• The received amounts for remunerated activities.</li> </ul>	<p>[Please describe your role.]</p>
<p>3. Did you have a membership in national or international:</p> <ul style="list-style-type: none"> <li>• organisations</li> <li>• committees, working groups</li> <li>• collaborative platforms</li> <li>• managing bodies</li> <li>• scientific advisory bodies</li> </ul> <p>(e.g. Commission expert groups, EU agencies or international organisations) with interest related to topics of the ECIBC?</p>	<p>Yes <input checked="" type="checkbox"/></p> <p>No <input type="checkbox"/></p>	<p>01/2017 – 12/2021</p>	<p>Member of the S3-Guideline Work Group “Breast Cancer” as team leader - public President of the DGS (German Society of Senology) Public</p>	

Activities in the last five years (January 2017- December 2021)	Yes/No	Period (From – To)	Information	Details
<p><b>4. Have you been an investigator in research studies with relevance to the topics of the ECIBC?</b></p>	<p>Yes <input checked="" type="checkbox"/> No <input type="checkbox"/></p>	<p>01/2017 12/2021</p>	<ul style="list-style-type: none"> <li>• Retrospective analysis of adjuvant oral therapy with abemaciclib based on the monarchE trial.</li> <li>• Development of a Comprehensive Risk Prediction Model fuer BRCA1 and BRCA2 mutation carriers</li> <li>• Pertuzumab in the first-line treatment of patients with metastatic HER2-positive breast cancer: a cohort study for patients treated with either docetaxel and trastuzumab or docetaxel, trastuzumab, and pertuzumab</li> <li>• Diagnostic Evaluation of PIK3CA mutations in circulating ctDNA and tumor tissue</li> <li>• A national, multicenter, open-label phase IIIb study of the treatment of women with hormone receptor-positive locally advanced or metastatic breast cancer with ribociclib (LEE011) in combination with letrozole</li> <li>• Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers</li> <li>• Therapy Management With Nab-Paclitaxel in Daily Routine</li> <li>• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer</li> <li>• Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial</li> </ul>	<p>PI/not yet published</p> <p>PI/not yet published</p> <p>PI not yet published</p> <p>PI not yet published</p> <p>PI not yet published</p> <p>PI not yet published</p> <p>PI not yet published</p> <p>PI not yet published</p> <p>PI not yet published</p>

Activities in the last five years (January 2017- December 2021)	Yes/No	Period (From – To)	Information	Details
			<ul style="list-style-type: none"> <li>Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial</li> </ul>	PI not yet published

Activities in the last five years (January 2017- December 2021)	Yes/No	Period (From – To)	Information	Details
<p><b>5. For the mentioned research studies (under point 4), did you receive research support?</b></p>	<p>Yes <input checked="" type="checkbox"/> No <input type="checkbox"/></p>	<p>01/2017 – 12/2021</p>	<ul style="list-style-type: none"> <li>• Pertuzumab in the first-line treatment of patients with metastatic HER2-positive breast cancer: a cohort study for patients treated with either docetaxel and trastuzumab or docetaxel, trastuzumab, and pertuzumab</li> <li>• A national, multicenter, open-label phase IIIb study of the treatment of women with hormone receptor-positive locally advanced or metastatic breast cancer with ribociclib (LEE011) in combination with letrozole</li> <li>• Feasibility of Lifestyle Intervention in BRCA1/2 Mutation Carriers</li> <li>• Therapy Management With Nab-Paclitaxel in Daily Routine</li> <li>• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer</li> <li>• Sentinel Node Biopsy in Breast Cancer: Omission of Axillary Clearance After Macrometastases. A Randomized Trial</li> <li>• Comparison of axillary sentinel lymph node biopsy versus no axillary surgery in patients with early-stage invasive breast cancer and breast-conserving surgery: a randomized prospective surgical trial</li> </ul>	<p>Fund – Roche Pharma AG, Private, 733.000 €</p> <p>Fund – Novartis Pharma GmbH, Private, 107.630 €</p> <p>Fund - Women's Hospital Rechts der Isar, Munich, Public, 7.748 €</p> <p>Fund – Celgene GmbH, Private, 745.000 €</p> <p>Fund – Novartis Pharma GmbH, Private, 107.950 €</p> <p>Fund – Karolinska Institutet, Stockholm, Public, 1.820 €</p> <p>Fund – University of Rostock, Public 1.500 €</p>

Activities in the last five years (January 2017- December 2021)	Yes/No	Period (From – To)	Information	Details
6. Do you have intellectual property rights (IPR) related to the topics of the ECIBC (e.g. patents, trademarks, copyrights)?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	01/2017 – 12/2021	Please specify the title of the IPR.	[Please describe the IPR.]
7. Did any of your immediate family members have direct interests related to the topics of the ECIBC that could undermine your independence?	Yes <input type="checkbox"/> No <input checked="" type="checkbox"/>	01/2017 – 12/2021	Please mention the interest.	[Please describe the interest.]
8. Did you take part in other activities with interests related to the topics of the ECIBC?	Yes <input checked="" type="checkbox"/> No <input type="checkbox"/>	01/2017 – 12/2021	AstraZeneca Education/Training Novartis Advisory Boards Pfizer Advisory Boards Roche Education/Training Sanofi Advisory Board Teva Lecture Medtronic Lecture Sanofi Advisory Board	Honorary Personal + Institutionell Honorary Personal + Institutionell Honorary Personal + Institutionell Honorary Personal Honorary Personal Honorary Personal Honorary Personal Honorary Personal Honorary Personal Honorary Personal

**Notes:**

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published<sup>2</sup> before you send the DoI form to the Joint Research Centre (JRC), European Commission.

After submission of this form, you need to inform the JRC in case of any new activity by sending a message as soon as possible to [JRC-CANCER-POLICY-SUPPORT@ec.europa.eu](mailto:JRC-CANCER-POLICY-SUPPORT@ec.europa.eu).

- I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.
- I agree my DoI form to be publicly available on the JRC Healthcare Quality website, during the European Commission Initiative on Breast Cancer working group membership<sup>3</sup>.
- I am informed that my personal data are stored, ~~processed and published~~ by the European Commission in accordance with Regulation (EU) 2018/1725<sup>4</sup>.

Name and Surname: Prof. Brucker, Sara Date: 13/05/2021

Signature:



Place: Tuebingen

<sup>2</sup>Personal data processing including the Declaration of Interests  
<https://ec.europa.eu/dpo-register/detail/DPR-EC-000656>

<sup>3</sup>Note: Technical measures are in place to ensure that search engines do not index the content from the Declaration of Interests form.

<sup>4</sup>Protection of individuals with regard to the processing of personal data  
<https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725>